StockData
Telomir Pharmaceuticals, Inc. logo

Telomir Pharmaceuticals, Inc. (TELO) stock

TELONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.42−0.06 (-12.04%)

Close on Nov 17, 2026Market cap $29.10MP/E –Yield –

Telomir Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Telomir Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.46M, up 74.7% year over year. For fiscal 2025 it was $2.44M, up 9.0% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.44M+9.0%
FY2024Dec 31, 2024$2.24M+42.0%
FY2023Dec 31, 2023$1.57M+88.9%
FY2022Dec 31, 2022$833.21K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$251.89K-66.8%
Q2 FY2026Jun 30, 2026$444.67K+938.0%
Q1 FY2026Mar 31, 2026$467.80K+38.8%
Q4 FY2025Dec 31, 2025$1.30M+381.7%
Q3 FY2025Sep 30, 2025$759.53K+21.1%
Q2 FY2025Jun 30, 2025$42.84K-92.8%
Q1 FY2025Mar 31, 2025$337.00K-58.1%
Q4 FY2024Dec 31, 2024$269.08K+32.0%
Q3 FY2024Sep 30, 2024$627.43K+139.0%
Q2 FY2024Jun 30, 2024$594.80K-10.9%
Q1 FY2024Mar 31, 2024$804.02K+82.6%
Q4 FY2023Dec 31, 2023$203.78K–
Q3 FY2023Sep 30, 2023$262.56K–
Q2 FY2023Jun 30, 2023$667.63K–
Q1 FY2023Mar 31, 2023$440.34K–

More Telomir Pharmaceuticals figures

See a number that looks wrong?